The below agenda is presented in CST / HKT.
-
Not only the cause for the most profound economic crisis since the Global Financial Crisis, but COVID-19 was also a wake-up call to better prepare for global pandemics and public health emergencies. After several years’ growth in the greater China region, Healthcare and life science sector are firm back under the spotlight, as being one of the most resilient industries in investment and M&A.
Unlike the M&A slump in major traditional sectors, biotech in China and Hong Kong enjoyed a 78% year-on-year growth in M&A deal value in 1H 2020, as well as being the most robust subsector to recover in 2Q. The biotech listing boom in HKEX remains and was further fueled by dual-listing candidates from NYSE or Shanghai’s STAR board. Pharma, Medical and Biotech together recorded 67 deals worth USD 6.9bn in 1H.
There are mixed views on whether the biotech trend will continue, or investors will take a more conservative approach and manage their expectation in profit return in a post-COVID world. While valuation could be at the center of the discussion as now is the time for dealmakers to rebuild deal pipelines and to restart negotiation. -
10:45
Time to Login to the Virtual Briefing
-
11:00
Live Virtual Briefing Starts
In this live session, we take stock of M&A activity in the Healthcare and Life Sciences sector in Mainland China, including:
• Overview of M&A H1 activity and insights in Healthcare
• Future investment hotspots in the next 6-12 months? Where is PE/VC focus right now?
• How should deal makers take advantage of (any) regulatory changes to grasp next deal opportunities?
• How are M&A transactions being transformed post-COVID-19 and in the time of social distancing? -
11:45
Live Q&A
-
12:00
Live Virtual Briefing Ends
Confirm cancellation
An error occurred trying to play the stream. Please reload the page and try again.
Close
Managing Director and Head of Everbright Healthcare Fund. Prior to Everbright, Mr. Fu worked as head of healthcare PE at Hillhouse, head of China healthcare at TPG Growth Capital, head of healthcare at FountainVest Partners and CITIC Pacific.
Mr. Fu has over 16 years’ experiences in investment, transactions range from early stage, growth to buyout. He has led and participated in investments in CP Guojian, CITIC Pharma, Lifetech, Fussen, Wuxi, Daopei, Amcare, Junshi and etc.
Prior to investment career, Mr. Fu had 8 years’ experience in operation with Sanjiu Pharmaceutical. He was the National Head of Sales and Marketing, responsible for both in-house products and exclusive agency business with multinational pharmaceutical companies.
Mr. Fu received MBA from University of British Columbia and Bachelor Degree of Economics and International Finance from East China Normal University. He is a CFA Charter holder as well.
刘晓岚先生2006年加入中信证券，拥有超过10年的医疗健康行业投行工作经验。曾作为项目负责人或现场负责人参与了以岭药业、中信国健、滇虹药业、益丰药房、沈阳三生、大理药业、赛诺医疗（科创板）等IPO项目、南京医药再融资、益丰药房可转债、哈药股份重大资产重组、益丰药房重大收购项目，并在灵康药业及甘李药业IPO等项目担任核心成员或技术支持工作。此外还参与了部分非医药类项目，包括中化国际分离交易可转债、中华企业再融资、南京新百重大资产重组、印度公司并购境内塑料制品企业等项目，拥有丰富的资本运作及项目经验。
刘晓岚先生毕业于加拿大McMaster大学，获工商管理硕士学位。
Mr. Josh SHIN specializes in Mergers & Acquisitions, equity financing and advices on regulatory issues, with a strong track record in various industry sectors such as pharma, life science, healthcare, education and general industry. He currently acts as coordinator of Fangda’s healthcare practices, and has been named as leading individual in life sciences by Chambers Asia Pacific and Legal 500 for years.
Speaker bio coming soon
As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare. At Jefferies, Mr. Zhu advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office, occupying a succession of positions culminating in Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Mr. Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry. Mr. Zhu earned his MBA from Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a Chartered Financial Analyst (CFA) charterholder.
Toto Ku is the Head of Greater China at Datasite (formerly Merrill Corporation), responsible for the company’s rapid growth in the mainland. He leads the expansion of Datasite’s footprint in the market, now trusted by thousands of corporates and PEs in China to securely source, manage and execute their deals and transactions faster.
Toto has more than 10 years’ experience in the finance industry, holding senior management roles in portfolio companies of KKR, Bain Capital and other global organizations, with a focus on financial technologies.
He specializes in helping global companies establish their footprint in China, successfully developing multiple opportunities for business growth over the past decade. Toto also has set up several real estate brokerage firms in Hong Kong serving hedge funds and PEs.
Yiqing Wang is China Editor/Head of APAC Editorial Operations for Mergermarket, a global news intelligence service for advisors, private equity firms and corporates. She leads a team of dedicated journalists across Greater China to cover PE/VC fundraising, M&A deals, PE buyouts and China cross-border M&A intelligence.
Yiqing has been an investigative M&A reporter and researcher since 2009, writing industry news ranging from healthcare, new energy and financial service, etc. She achieved her master’s degree of multilingual multicultural studies from New York University.